Litcius/Paper detail

Nicotinamide for the treatment of heart failure with preserved ejection fraction

Mahmoud Abdellatif, Viktoria Trummer-Herbst, Franziska Koser, Sylvère Durand, Rui Adão, Francisco Vasques‐Nóvoa, Johanna K. Freundt, Julia Voglhuber, María Rosaria Pricolo, Michael Kasa, Clara Türk, Fanny Aprahamian, Elías Herrero‐Galán, Sebastian J. Hofer, Tobias Pendl, Lavinia Rech, Julia Kargl, Nathaly Anto-Michel, Senka Ljubojević-Holzer, Julia Schipke, Christina Brandenberger, Martina Auer, Renate Schreiber, Chintan N. Koyani, Ákos Heinemann, Andreas Zirlik, Albrecht Schmidt, Dirk von Lewinski, Daniel Scherr, Peter P. Rainer, Julia von Maltzahn, Christian Mühlfeld, Marcus Krüger, Saša Frank, Frank Madeo, Tobias Eisenberg, Andreas Prokesch, Adelino Leite‐Moreira, André P. Lourenço, Jorge Alegre‐Cebollada, Stefan Kiechl, Wolfgang A. Linke, Guido Kroemer, Simon Sedej

2021Science Translational Medicine210 citationsDOIOpen Access PDF

Abstract

precursors, and especially nicotinamide, as potential therapeutic agents to treat diastolic dysfunction and HFpEF in humans.

Topics & Concepts

Ejection fractionHeart failureNicotinamideCardiologyInternal medicineMedicineChemistryFraction (chemistry)BiochemistryChromatographyEnzymeCardiovascular Function and Risk FactorsCardiac Ischemia and ReperfusionCardiac electrophysiology and arrhythmias